SOPH Company Profile and Key Details

SOPHiA GENETICS S.A. (NASDAQ:SOPH) closed at $5.76 USD, gaining $0.21 (3.78%) from the previous close of $5.55. The stock is currently mid-range between its 52-week high and low $2.92 and $6.77. With a market capitalization of about $395.93 million, SOPHiA GENETICS S.A. is classified as a small-cap and shows market-like volatility (beta ~0.96). Key stats such as the average daily volume over the past year has been around 241.31 thousand shares, in line with its 52-week average. Headquartered in Rolle, VD, SOPHiA GENETICS S.A. operates in the Healthcare sector and the Medical - Healthcare Information Services industry. Led by CEO Ross Muken, the company employs approximately 415 people and listed since July 23, 2021. SOPHiA GENETICS S.A.

Short-term trend indicators are mixed aligned (SMA20 -5.35%, SMA50 -7.02%, SMA200 14.1%). The stock’s 14-day RSI is 38.62 (weak momentum), while the ATR of 0.27 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -19.82% below its high and over 77.13% above its low. Average 10-day trading volume of 317.34 thousand shares is slightly above the 3-month average of 244.20 thousand, indicating heightened recent market interest.

SOPHiA GENETICS S.A. trades at a P/E ratio of -4.95, slightly below the S&P 500 average, with a price-to-sales ratio of 4.94 and a price-to-book ratio of 9.09 trading at moderately above to book value. The P/FCF stands at -8.84, also below market averages.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

SOPHiA GENETICS S.A. generated EPS of -$1.12 over the past year. Five-year average earnings growth is -12.32%. Wall Street analysts project EPS growth of 8.2% annually over the next five years. The latest quarter delivered EPS of -$0.27. The next quarter is forecast at -$0.24. Next year's EPS is expected at $22.92. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 6 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $12.00 to $7.00. The high target offers 108.33% upside. The low target suggests 21.53% downside. The mean target is $8.33. This offers 44.62% upside. SOPHiA GENETICS S.A. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended May 05, 2026, missed forecasts by 16.13%. The prior quarter beat by 17.89%. Over the last six quarters, Apple has recorded several small beats. These include 0.0% in March 04, 2025.

SOPHiA GENETICS S.A. has 83.90 million shares outstanding. The public float is 54.74 million shares, elevated short interest at 0.84% of float. This equals 661.35 thousand shares. The short ratio is 1.74 days. Institutional investors hold 51.62% of the float. Insiders own 7.03%. Camblong Jurgi holds 3.49 million shares, Muken Ross has 670.65 thousand shares and Xu Zhenyu has 610.89 thousand shares. Over the past six months, insider transactions show net selling. They sold 412.85 thousand shares across 98 transactions.

Our AI price prediction model suggests that SOPHiA GENETICS S.A. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 1.74%, with price expected at $5.86 by August 12, 2026, within a range of $5.55 to $6.16 3-Month Outlook: Projected rise of 7.12%, reaching $6.17 by October 27, 2026, with a range of $6.01 to $6.33. 1-Year Outlook: Projected gain of 409.2%, with price at $29.33 by July 29, 2027, within a range of $29.27 to $35.52.